Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Learn what tax lots are in automated investing, why they matter for cost basis and tax reporting, and how to use them to optimize your portfolios.
14,599 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Memory chips sit at the heart of AI infrastructure. As demand climbs, investors ask if will memory giants micron can ...
Three giants of U.S. banking posted strong Q1 results, yet each faces a different market reality. JPMorgan sits near ...
Banks are expanding infrastructure to monetize Bitcoin exposure without holding coins. Strategy's 32% adoption score ...
Microsoft has pulled back from recent highs, stirring questions about its value versus the S&P 500. This guide explai...
A practical, investor-focused look at Kestra Medical's (KMTS) 2026 earnings trajectory. We unpack expected revenue dr...
IBM recently released a preliminary quarter that underscored a broader pattern: AI budgets are shifting. This article...
CoreWeave has dropped substantially from its 52-week peak, leaving investors debating whether the bounce is coming or...
Nvidia could be headed toward a $300 stock price as AI demand, margins, and strategic bets align. This article breaks...
Investors chasing SpaceX-style wins without a private bet must weigh public players carefully. This guide compares AS...
When SpaceX delays its Starship launch, traders take note. But the real question for investors isn’t the setback itse...
In 2026, two retail powerhouses—Chewy and Walmart—face very different growth paths. This guide dissects their models,...